Relief from Hectic Life Styles: Scientifically Proven Solution to Hyper Acidity by Abbot’s Digene

IMT News Desk
IMT News Desk
· 3 min read

New market research shows that lifestyle-related hyperacidity is a growing concern for consumers. In fact, 61 per cent of the population in urban India suffers from hyperacidity at some point in time. Abbott’s Digene, one of the key antacid brands in the country, is a scientifically proven solution to hyperacidity for modern-day hectic lifestyles.

While hyperacidity has traditionally been associated by consumers with life-stage or body type, new market research shows that consumers believe hyperacidity is increasingly rooted in the lifestyle they lead. Due to the pressures of urban life, consumers report consumption of more culprit foods than ever, erratic eating habits and an increase in stress and tension. And data from one study found that nearly 70 per cent of acid reflux patients were aged below 50 years. This indicates that hyperacidity and related conditions are increasingly being driven by lifestyle factors and are thus more prevalent among younger populations.

Digene is uniquely suited to address this growing problem. The product has been available in India for nearly 90 years, and is the one prescribed antacid among doctors. Moreover, its efficacy is rooted in science. Digene has what is called high acid neutralizing capacity (ANC), which means it is very effective at reducing the acid in a person’s stomach to give them relief.

Dr. Srirupa Das, Director, Medical Affairs at Abbott explains, “Digene provides fast and effective relief based on science, with active ingredients that relieve symptoms and protect the stomach lining. This translates into better relief – which means people can get back to living their life.”

 Moreover, Digene is the only antacid in India that is available in three formats, liquid, powder and tablet. It is easy to consume both at home and on the go.

In order to meet the underlying need and reach a broader audience, Digene has launched a new campaign focusing on providing a scientific solution to lifestyle-related hyperacidity, with the versatile Tapsee Pannu who talks about the issues related to life-style related hyperacidity. She represents the challenges and problems faced by modern day consumers.

Commenting on the scientific approach presented to younger consumers, Ambati Venu, Managing Director, Abbott India Limited said, “Research indicates one of the leading causes of hyperacidity is hectic and erratic lifestyle, which is common among today’s urban consumers. Digene is an effective solution that is trusted by most doctors in India. Importantly, the product is backed by science through its high acid neutralizing capacity. As we further grow our consumer portfolio in the country, Abbott is committed to providing scientific solutions to help people get and stay healthy.”

 

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk